

Title (en)
USE OF PYRAZOLO 4,3-D PYRIMIDINES

Title (de)
VERWENDUNG VON PYRAZOLO 4,3-D PYRIMIDINEN

Title (fr)
UTILISATION DE PYRAZOLO 4,3-D PYRIMIDINES

Publication
EP 1357904 A2 20031105 (DE)

Application
EP 01997300 A 20011029

Priority
• DE 10058662 A 20001125
• EP 0112493 W 20011029

Abstract (en)
[origin: WO0241880A2] The invention relates to the use of pyrazolo[4,3-d]pyrimidines of formula (I) - wherein R<1>, R<2>, R<3>, R<4> and X have the designations cited in claim 1 - and the physiologically acceptable salts and/or solvates thereof, for producing a medicament for the treatment of angina, hypertension, pulmonary hypertension, congestive heart failure, arteriosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, apoplexy, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, kidney failure, and cirrhosis of the liver, and for the treatment of female sexual disorders.

IPC 1-7
A61K 31/00

IPC 8 full level
A61K 31/00 (2006.01); **C07D 487/04** (2006.01); **A61K 31/519** (2006.01); **A61P 1/00** (2006.01); **A61P 1/02** (2006.01); **A61P 1/04** (2006.01); **A61P 1/16** (2006.01); **A61P 9/00** (2006.01); **A61P 9/04** (2006.01); **A61P 9/08** (2006.01); **A61P 9/10** (2006.01); **A61P 9/12** (2006.01); **A61P 9/14** (2006.01); **A61P 11/00** (2006.01); **A61P 11/02** (2006.01); **A61P 11/06** (2006.01); **A61P 11/08** (2006.01); **A61P 13/12** (2006.01); **A61P 15/00** (2006.01); **A61P 15/10** (2006.01); **A61P 15/12** (2006.01); **A61P 27/06** (2006.01); **A61P 35/00** (2006.01); **A61P 37/08** (2006.01)

CPC (source: EP KR US)
A61K 31/519 (2013.01 - EP US); **A61P 1/00** (2018.01 - EP); **A61P 1/02** (2018.01 - EP); **A61P 1/04** (2018.01 - EP); **A61P 1/16** (2018.01 - EP); **A61P 7/00** (2018.01 - EP); **A61P 9/00** (2018.01 - EP); **A61P 9/04** (2018.01 - EP); **A61P 9/08** (2018.01 - EP); **A61P 9/10** (2018.01 - EP); **A61P 9/12** (2018.01 - EP); **A61P 9/14** (2018.01 - EP); **A61P 11/00** (2018.01 - EP); **A61P 11/02** (2018.01 - EP); **A61P 11/06** (2018.01 - EP); **A61P 11/08** (2018.01 - EP); **A61P 13/12** (2018.01 - EP); **A61P 15/00** (2018.01 - EP); **A61P 15/10** (2018.01 - EP); **A61P 15/12** (2018.01 - EP); **A61P 27/06** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 37/08** (2018.01 - EP); **C07D 487/04** (2013.01 - KR)

Cited by
US11725395B2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated extension state (EPC)
LT LV RO SI

DOCDB simple family (publication)
WO 0241880 A2 20020530; **WO 0241880 A3 20030828**; AR 035373 A1 20040512; AU 1597902 A 20020603; BR 0115187 A 20040120; CA 2429645 A1 20020530; CN 1665508 A 20050907; CZ 20031668 A3 20031015; DE 10058662 A1 20020529; EP 1357904 A2 20031105; HU P0302720 A2 20031128; JP 2004513963 A 20040513; KR 20030051870 A 20030625; MX PA03004498 A 20030905; PL 363077 A1 20041115; RU 2003117477 A 20041127; SK 7592003 A3 20031104; US 2004023990 A1 20040205; ZA 200304908 B 20040728

DOCDB simple family (application)
EP 0112493 W 20011029; AR P010105461 A 20011123; AU 1597902 A 20011029; BR 0115187 A 20011029; CA 2429645 A 20011029; CN 01819428 A 20011029; CZ 20031668 A 20011029; DE 10058662 A 20001125; EP 01997300 A 20011029; HU P0302720 A 20011029; JP 2002544059 A 20011029; KR 20037006947 A 20030523; MX PA03004498 A 20011029; PL 36307701 A 20011029; RU 2003117477 A 20011029; SK 7592003 A 20011029; US 43277203 A 20030527; ZA 200304908 A 20030624